三尖瓣反流经导管治疗的中国专家共识  

Chinese expert consensus on transcatheter tricuspid valve intervention therapy

作　　者：中国医师协会心血管内科医师分会结构性心脏病学组 无 潘文志[3] 宋光远 周达新 吴永健 刘先宝[5] 陆方林 张晓春[3] 葛均波(指导)[3] 王建安(指导)[5] Chinese College of Cardiovascular Physicians Structural Cardiology Group,China Heart House;PAN Wen-zhi;SONG Guang-yuan;ZHOU Da-xin;WU Yong-jian

机构地区：[1]不详 [2]苏州工业园区东方华夏心血管健康研究院 [3]复旦大学附属中山医院 [4]首都医科大学附属北京安贞医院 [5]浙江大学医学院附属第二医院 [6]上海市第一人民医院

出　　处：《中国介入心脏病学杂志》2024年第10期551-561,共11页Chinese Journal of Interventional Cardiology

摘　　要：三尖瓣反流(TR)是较常见的心脏瓣膜疾病之一,既往标准治疗为外科手术,但该方法创伤大、风险高。近年来,经导管三尖瓣介入治疗(TTVI)技术实现重大突破,在国外已步入临床推广阶段,并且相继推出了TTVI专家共识文件。但在我国,目前仍缺乏该方面的共识性文件。为推进该技术在我国安全、规范、健康地发展,特编写此专家共识。本共识将从TR的解剖与流行病学、分类与发病机制、传统治疗与TTVI、TTVI术前评估及临床疗效终点等方面予以介绍,并梳理总结10个核心观点,以便读者能够快速掌握共识的精髓要点。Tricuspid regurgitation(TR)is a common heart valve disease traditionally treated with surgery,which is invasive and high-risk.Recently,transcatheter tricuspid valve intervention(TTVI)technology has achieved major breakthroughs.It is being promoted internationally and several expert consensus documents have been launched abroad.However,in China,there is still a lack of consensus documents in this regard.In order to promote the safe,standardized and healthy development of this technology,this expert consensus is specially compiled.This consensus will introduce anatomy,epidemiology,classifi cation and pathogenesis of TR,the traditional treatment and TTVI,preoperative evaluation and clinical efficacy endpoints.We sort out ten core viewpoints so that readers can quickly grasp the essence of the consensus.

关 键 词：三尖瓣反流 经导管三尖瓣介入 专家共识 

分 类 号：R54[医药卫生—心血管疾病]